Boron trioxide-alumina as a heterogeneous catalyst in a facile solvent free one-pot synthesis of 3,4-dihydropyrimidin-2(1*H*)-ones Xufeng Zhou^b, Tianxing Cheng^a*, Xiangyong Zheng^c, Qiang Ke^c and Xuebao Wang^{a,d}

^aThe Key Laboratory of Leather Engineering of Zhejiang Province, College of Chemistry and Materials Engineering, Wenzhou University, Wenzhou 325027, P. R. China

^bOujiang College, Wenzhou University, Wenzhou 325035, P. R. China

°College of Life and Environmental Sciences, Wenzhou University, Wenzhou 325035, P. R. China

^dAnalytical and Testing Center, Wenzhou Medical College, Wenzhou 325035, P. R. China

 B_2O_3/AI_2O_3 has been found to be a new and highly efficient heterogeneous catalyst for the one-pot synthesis of 3,4-dihydropyrimidin-2(1*H*)-ones by the Biginelli reaction under solvent-free conditions. 3,4-Dihydropyrimidin-2(1*H*)-ones have important pharmacological and biological activities.

Keywords: B₂O₃/Al₂O₃, 3,4-dihydropyrimidin-2(1*H*)-ones, Biginelli reaction, solvent-free synthesis

3,4-Dihydropyrimidin-2(1H)-ones¹ have recently attracted interest because of their wide range of pharmacological and biological activities.²⁻⁵ In 1893, Biginelli was the first to synthesise 3,4-dihydropyrimidin-2(1H)-ones by the one-pot three-component condensation reaction of an aromatic aldehyde, urea, and ethyl acetoacetate.6 However, the original reactions often afforded poor to moderate yields and were conducted under strongly acidic conditions.⁷ These might limit the scope of the reaction. Consequently, many improved methods have been reported for the synthesis of 3,4-dihydropyrimidin-2(1H)-ones in the presence of various catalysts.⁸⁻²² Although the reported methodologies are suitable for certain syntheses, some of these procedures suffer from disadvantages, such as a long reaction time, low yield, the use of volatile organic solvents, requirement of excess reagents or costly catalysts and harsh reaction conditions. Owing to the importance of 3,4dihydropyrimidin-2(1H)-ones from the pharmaceutical, industrial and synthetic points of view, introduction of an efficient method for the preparation of these compounds is still in demand.

In recent years, heterogeneous organic reactions have been recently performed with immobilised reagents on solid supports.²³ These procedures offer several intrinsic advantages such as clean reactions, easy separation of the products, the recovery and reuse of catalyst, and the minimisation of waste production. To the best of our knowledge, only two examples have been described in which B_2O_3/Al_2O_3 as a heterogeneous catalyst has been used for the synthesis of β -amino alcohols²⁴ and β -enamino ketones/esters²⁵ in the field of organic synthesis.

As part of our continuing interest in the development of new synthetic methodologies,^{26,27} we report that B_2O_3/Al_2O_3 is an efficient heterogeneous catalyst for the synthesis of 3,4-dihydropyrimidin-2(1*H*)-ones by the Biginelli reaction under solvent-free conditions.

Initially, the one-pot, three-component reaction of benzaldehyde, ethyl acetoacetate and urea was chosen as a model reaction to identify the optimal reaction conditions. The results are listed in Table 1. First, the effect of solvents was tested. Among the solvents screened (*e.g.* CH₃CH₂OH, CH₃CN, CH₂Cl₂, and THF), ethanol is a better solvent than other solvents tested (Table 1, entries 1–4). We were pleased to discover that the reaction occurred efficiently to afford the corresponding 3,4-dihydropyrimidin-2(1*H*)-one **4a** in 88% yield when 0.03 g B₂O₃/Al₂O₃ and 1–1.15 mmol substrates were used under solvent-free conditions (Table 1, entry 6). Moreover, we observed that the yields were affected by the amount of B₂O₃/ Al₂O₃ that was used and by the reaction temperature. Decreasing the amount of the catalyst or the reaction temperature led

* Correspondent. E-mail: chengtx_wzu@163.com

 Table 1
 Optimisation of the reaction conditions^a

PhCHO + 1a	EtO 2a	+ H ₂ N NH ₂ 3a	B₂O₃/Al₂O₃ solvent	Eto Ph NH H 4a
Entry	Solvent	Temp./ºC	Time/h	Yields/%
1	CH₃CH₂OH	75	4	58
2	CH₃CN	75	4	50
3	CH_2CI_2	40	4	43
4	THF	60	4	32
5	none	75	4	86
6	none	75	6	88
7	none	50	6	71
8	none	90	3	85
9	none	75	4	73 ^b
10	none	75	4	87°
11	none	75	4	38 ^d
12	none	75	6	Trace ^e

^aAll reactions were run with 1a (1.0 mmol), 2a (1.5 mmol), 3a (1.0 mmol) and B_2O_3/Al_2O_3 (0.03 g, 15% w/w) in 3 mL of solvent at 75 °C. Isolated yield.

 $^{\rm b}{\rm B_2O_3/Al_2O_3}$ (0.01 g, 15% w/w) was used as a catalyst.

 $^{\circ}B_2O_3/Al_2O_3$ (0.04 g, 15% w/w) was used as a catalyst.

 ${}^{\rm d}{\rm Al}_2{\rm O}_3$ (0.02 g) was used as a catalyst.

^eWithout catalyst.

to lower yields (Table 1, entries 6–10) of the product. On the other hand, **4a** was obtained in 38% yield when only Al_2O_3 was used as a catalyst (Table 1, entry 11). In contrast, only a trace amount of the product was obtained in the absence of B_2O_3/Al_2O_3 (Table 1, entry 12), which provided further proof that B_2O_3/Al_2O_3 plays an important role in this transformation.

Having the optimal conditions in hand, the substrate scope of the Biginelli reaction was investigated, and several structurally diverse 3,4-dihydropyrimidin-2(1H)-ones **4** were prepared (Table 2).

As shown in Table 2, we investigated the influence of the electronic features of the aromatic aldehydes on the reaction. It was observed that the substituent group on the phenyl ring had no obvious effects on the yield of the Biginelli reaction (Table 2, entries 1–4). For example, *p*-fluorobenzaldehyde and *p*-methoxybenzaldehyde afforded the corresponding products **4b** and **4c** in 90% and 85% yields, respectively. Moreover, we also examined the one-pot, three-component reaction of aldehydes, dicarbonyl compounds and thiourea (Table 2, entries 5–9). The corresponding 3,4-dihydropyrimidin-2(1*H*)-thiones **4e–i** were also obtained in high yields. Aacetylacetone was also a good partner for the Biginelli reaction and the corresponding products **4j–l** were isolated in 91%, 89%, 87% yields,

 Table 2
 Scope for synthesis of 3,4-dihydropyrimidin-2(1*H*)-ones^a

ArCHO 1	+ R 2	+ H ₂ N	X NH ₂ 3	B ₂ O ₃ /Al ₂ O ₃ solvent-free	Ar NH NH X H
Entry	Ar	R	Х	Products	Yield/%
1	C_6H_5	OEt	0		88
2	<i>p</i> -(F)C ₆ H ₄	OEt	0	HN NH F 4b	90
3	<i>p</i> -(OMe)C ₆ H₄	OEt			
4	p-(Me)C ₆ H ₄	OEt	0	HN NH Me 4d	89
5	p-(OMe)C₀H₄	OEt	S		84
6	p-(Me)C ₆ H ₄	OEt	S		86
7	<i>p</i> -(F)C ₆ H ₄	OEt	S		91
8	p-(OMe)C₀H₄	CH₃	S	s	89
9	<i>p</i> -(F)C ₆ H ₄	CH₃	S		93
10	<i>p</i> -(OMe)C ₆ H₄	CH₃	0		j 91
11					89
12	C_6H_5	CH₃	0		87

°All reactions were run with 1 (1.0 mmol), 2 (1.5 mmol), 3 (1.0 mmol) and B_2O_3/Al_2O_3 (0.03 g, 15% w/w) at 75 °C for 6 h under solvent-free conditions. Isolated yield.

respectively (Table 2, entries 10–12). In general, B_2O_3/Al_2O_3 catalysed reactions proceeded smoothly and gave the corresponding products in good to excellent yields.

Conclusion

In summary, B_2O_3/Al_2O_3 is a highly efficient heterogeneous catalyst for the Biginelli reaction under solvent-free conditions, affording the corresponding 3,4-dihydropyrimidin-2(1*H*)-ones in good yields. The present protocol involves a simple work-up, is environmentally benign, and affords high yields using of the catalytic amounts of the cheap heterogeneous catalyst as well

as solvent-free conditions. Investigations on further application of the protocol are currently underway in our laboratory.

Experimental

Chemicals and apparatus

Unless otherwise noted, the reagents were purchased and used without further purification. NMR spectroscopy was performed on a Bruker-300 spectrometer using CDCl₃ as the solvent with tetramethylsilane (TMS) as an internal standard at room temperature. Chemical shifts are given in δ relative to TMS, the coupling constants *J* are given in Hz. Column chromatography was performed using EM Silica gel 60 (300–400 mesh). All known compounds afforded analytical data identical to those reported literature previously.

Typical procedure for the preparation of $B_2O_3/Al_2O_3^{28}$

85 g of γ -Al₂O₃ (JRC-ALO-7: 180 m² g⁻¹) was first impregnated with an aqueous solution of H₃BO₃ (26.64g of boric acid and 50 ml of water), followed by calcination at 773 K for 5 h. The B₂O₃ contents were 15 wt%. The white mixture (B₂O₃/Al₂O₃) of 100 g was obtained.

Synthesis of 3,4-dihydropyrimidin-2(1H)-ones; general procedure

 B_2O_3/Al_2O_3 (0.03 g, 15% w/w) was added to a magnetically stirred mixture of aldehyde (1 mmol), dicarbonyl compound (1.5 mmol), and urea or thiourea (1 mmol), and the reaction mixture was stirred at 75 °C for 6 h under solvent-free conditions. After the completion of the reaction, as monitored by TLC and GC-MS analysis, the reaction mixture was cooled to room temperature and diluted with ethyl acetate. The catalyst was separated by filtration, then the solution was washed with ethyl acetate and dried over anhydrous sodium sulfate, filtered and the solvent was evaporated under vacuum. The residue as an eluent to afford the pure product of 4. The physical and spectral data of compounds 4a-l are as follows.

Ethyl 6-*methyl*-2-*oxo*-4-*phenyl*-1,2,3,4-*tetrahydropyrimidine*-5-*carboxylate* (**4a**): Solid, m.p. 203–204 °C, (lit.¹⁴ 202–203 °C). ¹H NMR (300 MHz, CDCl₃): δ ppm 8.12 (br s, 1H, NH), 7.25–7.32 (m, 5H), 5.76 (br s, 1H, NH), 5.40 (d, J = 2.74 Hz, 1H), 4.03 (q, J = 7.12 Hz, 2H), 2.34 (s, 3H), 1.59 (t, J = 7.12 Hz, 3H). ¹³C MNR (75 MHz, CDCl₃): δ ppm 128.7, 127.9, 126.6, 101.3, 60.0, 55.7, 18.6, 14.1.

Ethyl 4-(4-fluorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (**4b**): Solid, m.p. 175–176 °C, (lit.¹⁴ 171–173 °C). ¹H NMR (300 MHz, CDCl₃): δ ppm 8.64 (br s, 1H, NH), 7.25–7.30 (m, 2H), 6.95–7.00 (m, 2H), 6.29 (br s, 1H, NH), 5.37 (d, J = 2.22 Hz, 1H), 4.07 (q, J = 7.04 Hz, 2H), 2.32 (s, 3H), 1.04 (t, J = 7.04 Hz, 3H). ¹³C MNR (75 MHz, CDCl₃): δ ppm 165.5, 162.2 (¹ $J_{CF} = 244.86$ Hz), 153.7, 146.4, 139.6 (⁴ $J_{CF} = 3.08$ Hz), 128.2 (³ $J_{CF} = 8.18$ Hz), 115.4 (² $J_{CF} = 21.38$ Hz), 101.2, 60.0, 54.9, 18.5, 14.1.

Ethyl 4-(4-methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (**4c**): Solid, m.p. 192–193 °C, (lit.¹⁴ 190–192 °C). ¹H NMR (300 MHz, CDCl₃): δ ppm 8.24 (br s, 1H, NH), 7.23–7.28 (m, 2H), 6.83–6.86 (m, 2H), 5.80 (br s, 1H, NH), 5.38 (d, J = 2.54 Hz, 1H), 4.09 (q, J = 7.11 Hz, 2H), 3.80 (s, 3H), 2.34 (s, 3H), 1.18 (t, J = 7.11 Hz, 3H). ¹³C MNR (75 MHz, CDCl₃): δ ppm 165.7, 159.3, 153.5, 145.9, 136.1, 127.8, 114.0, 101.6, 59.9, 55.2, 18.6, 14.1.

Ethyl 6-*methyl*-2-*oxo*-4-*p*-*tolyl*-1,2,3,4-*tetrahydropyrimidine*-5-*carboxylate* (**4d**): Solid, m.p. 207–208 °C, (lit.¹⁹ 209–212 °C). ¹H NMR (300 MHz, CDCl₃): δ ppm 8.42 (br s, 1H, NH), 7.20–7.23 (m, 2H), 7.10–7.13 (m, 2H), 5.96 (br s, 1H, NH), 5.37 (d, J = 2.74 Hz, 1H), 4.08 (q, J = 7.10 Hz, 2H), 2.33 (s, 3H), 2.31 (s, 3H), 1.18 (t, J = 7.10 Hz, 3H). ¹³C MNR (75 MHz, CDCl₃): δ ppm 165.7, 153.6, 146.2, 140.9, 137.5, 129.3, 126.4, 101.4, 59.9, 55.3, 21.0, 18.5, 14.1.

Ethyl 4-(4-methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (**4e**): Solid, m.p. 125–126 °C, (lit.¹⁴ 123– 125 °C). ¹H NMR (300 MHz, CDCl₃): δ ppm 8.46 (br s, 1H, NH), 7.84 (br s, 1H, NH), 7.18–7.22 (m, 2H), 6.81–6.84 (m, 2H), 5.33 (d, J = 2.90 Hz, 1H), 4.08 (q, J = 7.11 Hz, 2H), 3.77 (s, 3H), 2.35 (s, 3H), 1.17 (t, J = 7.11 Hz, 3H). ¹³C MNR (75 MHz, CDCl₃): δ ppm 174.0, 165.3, 159.4, 142.6, 134.7, 128.0, 114.0, 103.0, 60.3, 55.4, 55.2, 18.0, 14.0.

Ethyl 6-*methyl*-2-*thioxo*-4-*p*-*tolyl*-1,2,3,4-*tetrahydropyrimidine*-5*carboxylate* (**4f**): Solid, m.p. 192–194 °C, (lit.¹⁴ 190–193 °C). ¹H NMR (300 MHz, CDCl₃): δ ppm 8.18 (br s, 1H, NH), 7.68 (br s, 1H, NH), 7.10–7.20 (m, 4H), 5.35 (d, J = 2.91 Hz, 1H), 4.09 (q, J = 7.11 Hz, 2H), 2.35 (s, 3H), 2.32 (s, 3H), 1.17 (t, J = 7.11 Hz, 3H). ¹³C MNR (75 MHz, CDCl₃): δ ppm 179.1, 170.0, 147.3, 144.2, 142.8, 134.2, 131.4, 107.7, 65.1, 60.6, 25.8, 22.9, 18.8. *Ethyl* 4-(4-fluorophenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (**4g**): Solid, m.p. 194–195 °C, (lit.²⁹ 191– 192 °C). ¹H NMR (300 MHz, CDCl₃): δ ppm 8.30 (br s, 1H, NH), 7.79 (br s, 1H, NH), 7.23–7.28 (m, 2H), 6.97–7.04 (m, 2H), 5.38 (d, J = 2.52 Hz, 1H), 4.05–4.15 (m, 2H), 2.36 (s, 3H), 1.15–1.26 (m, 3H). ¹³C MNR (75 MHz, CDCl₃): δ ppm 174.3, 165.1, 162.5 (¹J_{CF} = 245.78 Hz), 142.8, 138.3 (⁴J_{CF} = 3.15 Hz), 128.5 (³J_{CF} = 8.33 Hz), 115.8 (²J_{CF} = 21.68 Hz), 102.9, 60.5, 55.4, 18.2, 14.1.

1-(4-(4-Methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)ethanone (**4h**): Solid, m.p. 194–195 °C, (lit.²⁰ 191–192 °C). ¹H NMR (300 MHz, CDCl₃): δ ppm 7.87 (br s, 1H, NH), 7.39 (br s, 1H, NH), 7.15–7.26 (m, 4H), 5.40 (d, *J* = 2.37 Hz, 1H), 2.35 (s, 3H), 2.32 (s, 3H), 2.12 (s, 3H). ¹³C MNR (75 MHz, CDCl₃): δ ppm 195.3, 174.2, 141.5, 138.6, 138.5, 129.8, 126.7, 111.5, 56.3, 30.2, 21.1, 19.3.

l-(4-(4-Fluorophenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)ethanone (**4i**): Solid, m.p. 208–209 °C, (lit.²¹ 209–211 °C). ¹H NMR (300 MHz, CDCl₃): δ ppm 7.58 (br s, 1H, NH), 7.24–7.29 (m, 2H), 7.06 (br s, 1H, NH), 7.00–7.06 (m, 2H), 5.47 (d, J = 2.85 Hz, 1H), 2.36 (s, 3H), 2.18 (s, 3H). ¹³C MNR (75 MHz, CDCl₃): δ ppm 195.1, 174.5, 162.4 (¹J_{CF} = 242.55 Hz), 145.2, 129.6, 128.0 (³J_{CF} = 8.78 Hz), 115.8 (²J_{CF} = 21.30 Hz), 110.9, 53.4, 30.9, 18.7.

5-Acetyl-4-(4-methoxyphenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one (**4j**): Solid, m.p. 178–179 °C, (lit.²¹ 177–179 °C). ¹H NMR (300 MHz, CDCl₃): δ ppm 8.53 (br s, 1H, NH), 7.18–7.26 (m, 2H), 6.82–6.86 (m, 2H), 6.12 (br s, 1H, NH), 5.37 (d, *J* = 2.94 Hz, 1H), 3.77 (s, 3H), 2.31 (s, 3H), 2.09 (s, 3H). ¹³C MNR (75 MHz, CDCl₃): δ ppm 195.3, 159.4, 153.3, 145.7, 135.1, 127.8, 114.3, 110.6, 55.4, 55.2, 30.2, 19.5.

5-Acetyl-4-(4-fluorophenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one (**4k**): Solid, m.p. 257–259 °C, (lit.²² 260–261 °C). ¹H NMR (300 MHz, CDCl₃): δ ppm 8.44 (br s, 1H, NH), 7.24–7.29 (m, 2H), 6.97–7.03 (m, 2H), 6.08 (br s, 1H, NH), 5.44 (d, J = 2.94 Hz, 1H), 2.33 (s, 3H), 2.14 (s, 3H). ¹³C MNR (75 MHz, CDCl₃): δ ppm 194.9, 162.4 (¹ $_{JCF} = 245.78$ Hz), 153.0, 145.7, 128.3 (³ $_{JCF} = 8.25$ Hz), 115.9 (² $_{JCF} = 21.68$ Hz), 110.9, 55.1, 30.5, 19.7.

5-Acetyl-6-methyl-4-phenyl-3,4-dihydropyrimidin-2(1H)-one (**4**): Solid, m.p. 233–235 °C, (lit.²¹ 234–235 °C). ¹H NMR (300 MHz, CDCl₃): δ ppm 9.17 (br s, 1H, NH), 7.81 (br s, 1H, NH) 7.22–7.33 (m, 5H), 5.23 (d, J = 3.16 Hz, 1H), 2.27 (s, 3H), 2.08 (s, 3H). ¹³C MNR (75 MHz, CDCl₃): δ ppm 194.6, 152.5, 148.5, 144.6, 128.9, 127.7, 126.8, 109.9, 54.2, 30.7, 19.3.

We are grateful for financial support from the Science and Technology Department of Zhejiang Province (No. 2010C33061), the Opening Foundation of Zhejing Provincial Top Key Discipline (No. 100061200129), and the Wenzhou Science & Technology Bureau Program (No. S20100004).

Received 22 December 2011; accepted 18 February 2012 Paper 1101056 doi: 10.3184/174751912X13318334808777 Published online: 17 April 2012

References

- M. Matache, C. Dobrota, N.D. Bogdan and D.P. Funeriu, <u>*Curr. Org. Synth.*</u>, 2011, 8, 356.
- E. Rajanarendar, M.N. Reddy, K.R. Murthy, K.G. Reddy, S. Raju, M. Srinivas, B. Praveen and M.S. Rao, *Bioorg. Med. Chem. Lett.*, 2010, 20, 6052.
- J.C. Barrow, P.G. Nantermet, H.G. Selnick, K.L. Glass, K.E. Rittle, K.F. Gilbert, T.G. Steele, C.F. Homnick, R.M. Freidinger, R.W. Ransom, P. Kling, D. Reiss, T.P. Broten, T.W. Schorn, R.S.L. Chang, S.S. O'Malley, T.V. Olah, J.D. Ellis, A. Barrish, K. Kassahun, P. Leppert, D. Nagarathnam and C. Forray, *J. Med. Chem.*, 2000, 43, 2703.
- 4. C.O. Kappe, Eur. J. Med. Chem., 2000, 35, 1043.
- O.M. Singh, S.J. Singh, M.B. Devi, L.N. Devi, N.I. Singh and S.-G. Lee, Bioorg. Med. Chem. Lett., 2008, 18, 6462.
- 6. P. Biginelli, Gazz. Chem. Ital., 1893, 23, 360.
- J. Barluenga, M. Thomas, A. Ballesterus and A. Lopez, <u>*Tetrahedron Lett.*</u>, 1989, **30**, 4573.
- 8. See review: C. O. Kappe, Acc. Chem. Res., 2000, 33, 879.
- 9. J.Singh, N. Mahajan, R.L. Sharma and T.K. Razdan, J. Heterocycl. Chem., 2011, 48, 1398.
- K.S. Niralwad, B.B. Shingate and M.S. Shingare, *Tetrahedron Lett.*, 2010, 51, 3616.
- M. Kargar, R. Hekmatshoar, A. Mostashari and Z. Hashemi, *Catal. Commun.*, 2011, 15, 123.
- M.R.M. Bhojegowd, A. Siddaramanna, A.B. Siddappa, C.G. Thimmanna and M.A. Pasha, *Chin. J. Chem.*, 2011, 29, 1863.
- P. Li, S. Regati, R.J. Butcher, H.D. Arman, Z. Chen, S. Xiang, B. Chen and C. Zhao, *Tetrahedron Lett.*, 2011, 52, 6220.
- D.L. da Silva, S.A. Fernandes, A.A. Sabino and Â. de Fátima, *Tetrahedron Lett.*, 2011, **52**, 6328.
- 15. B. Ranu, A. Hajra and U. Jana, J. Org. Chem., 2000, 65, 6270.
- J.V. Kharchenko, O. Detistov and V.D. Orlov, J. Comb. Chem., 2009, 11, 216.
- 17. Z.-L. Shen, X.-P. Xu and S.-J. Ji, J. Org. Chem., 2010, 75, 1162.
- 18. S. Saha and J.N. Moorthy, J. Org. Chem., 2011, 76, 396.
- 19. H. Murata, H. Ishitani and M. Iwamoto, Org. Biomol. Chem., 2010, 8, 1202.
- J.C. Rodríguez-Domínguez, D. Bernardi and G. Kirsch, *Tetrahedron Lett.*, 2007, 48, 5777.
- H.R. Shateriana, A. Hosseiniana and M. Ghashanga, <u>Phosphorus, Sulfur</u> Silicon Relat. Elem., 2009, 184, 197.
- 22. S. Chitra and K. Pandiarajan, Tetrahedron Lett., 2009, 50, 2222.
- F. Tamaddon, M.A. Amrollahi and L. Sharafat, *Tetrahedron Lett.*, 2005, 46, 7841.
- C.F. Zhang, J.X. Chen, X.C. Yu, X.A. Chen, H.Y. Wu, <u>Synth. Commun.</u>, 2008, 38, 1875.
- J.X. Chen, C.F. Zhang, W.X. Gao, H.L. Jin, J.C. Ding and H.Y. Wu, *J. Braz. Chem. Soc.*, 2010, 21, 1552.
- H.L. Jin, T.X. Cheng and J.X. Chen, *Appl. Organometal. Chem.*, 2011, 25, 238.
- 27. T.X. Cheng, X.Y. Zheng and Q. Ke, J. Chem. Res., 2011, 35, 522.
- Usman, T. Kubota, Y. Araki, K. Ishida and Y. Okamoto, J. Catal., 2004, 227, 523.
- S.K. Nayak, K.N. Venugopala, D. Chopra, Vasu, T.N. Guru Row, Cryst Eng Comm., 2010, 12, 1205.